Background The Totaled Health Risks in Vascular Events (THRIVE) score strongly predicts clinical outcome, mortality, and risk of thrombolytic haemorrhage in ischemic stroke patients, and performs similarly well in patients receiving intravenous tissue plasminogen activator, endovascular stroke treatment, or no acute treatment. It is not known if the THRIVE score predicts outcomes with the Solitaire endovascular stroke treatment device.
Introduction
Several ischemic stroke outcome scores have been developed to predict outcomes among patients undergoing endovascular stroke treatment (EST) (1) (2) (3) . The THRIVE score was originally developed in the context of EST, using data from the MERCI and Multi-MERCI trials (2) . THRIVE has since been validated in EST using data from the Merci Registry (4) and using data from the TREVO-2 trial (5) . We have also found that the THRIVE score performs equally well in patients receiving tissue plasminogen activator (tPA) or no acute stroke treatment, using data from the NINDS tPA trial (6) and the Virtual International Stroke Trials Archive (7) .
We have found that the THRIVE score strongly predicts outcomes in the TREVO-2 trial, a randomized controlled trial (RCT) comparing the Merci device to the Trevo device, a type of retrievable stent (5) . Two retrievable stent EST devices (the Trevo device and Solitaire device) are now available, with each device having been found to be superior to a previous generation device (the Merci device) for both recanalization and clinical outcomes in two RCTs (8, 9) .
Here, we examine the utility of the THRIVE score in patients undergoing EST with the Solitaire device in two recently published clinical trials, the SWIFT trial (9) and the STAR trial (10) . We examine the relationship between THRIVE and outcomes in SWIFT and STAR, and then control for recanalization success and for treatment assignment (Solitaire vs. Merci device) in the SWIFT RCT. We then compare the performance of the THRIVE score with other clinical prediction scores in the context of the Solitaire device in acute ischemic stroke.
Aims
We sought to validate the relationship between the THRIVE score and outcomes after treatment with the Solitaire EST device.
Methods

Data source and subjects
We obtained demographic data, clinical data, three-month functional outcomes on the modified Rankin Scale (mRS), and threemonth mortality from the SWIFT trial and the STAR trial (9, 10) . SWIFT was a 146-patient trial of EST for acute ischemic stroke with two components: a run-in phase with 32 patients nonrandomly allocated to treatment with the Solitaire EST device and an RCT component with 58 patients randomized to the Solitaire device and 56 patients randomized to the Merci device, as previously described in detail (9) . The STAR trial was a prospective, single-arm trial of 202 acute stroke patients treated with the Solitaire device (10) . Institutional review board and regulatory approvals were obtained by participating centers in SWIFT and STAR (9, 10) , and no primary data or protected health information was transmitted outside the trial databases to the investigators of this report. The SWIFT and STAR trials were both registered with ClinicalTrials.gov (registration numbers NCT01054560 and NCT01327989).
Measurements
To calculate the THRIVE score, we noted age, initial stroke severity on the National Institutes of Health Stroke Scale (NIHSS) score, and the presence or absence of hypertension (HTN), diabetes mellitus (DM), or atrial fibrillation (AF). The THRIVE score assigns 1 point for age 60-79 years, 2 points for age ≥ 80 years, 2 points for NIHSS score 11-20, 4 points for NIHSS score ≥ 21, and 1 point each for HTN, DM, and AF (2) . Other clinical prediction scores [Houston Intra-Arterial Therapy score (HIAT), HIAT-2, and Stroke Prognostication using Age and NIH Stroke Scale score (SPAN)-100] were calculated as follows. HIAT assigns 1 point each for age > 75, NIHSS > 18, and glucose > 150 mg/dL (1).
HIAT-2 assigns 2 points for age 60-79, 4 points for age ≥ 80 years, 1 point for NIHSS score 11-20, 2 points for NIHSS score ≥ 21, and 3 points for Alberta Stroke Program Early Computed Tomography Score of ≤7·3 The SPAN-100 is a single point score -the score is positive if the sum of the patient's age and NIHSS is > 100 (11) .
Outcome measures were functional outcome on the mRS at three-months (with good outcome defined as mRS = 0-2 and poor outcome defined as mRS = 3-6) and mortality by threemonths. Successful recanalization was defined as a Thrombolysis in Cerebral Ischemia (TICI) score of 2b or 3 at the completion of the EST procedure.
Statistical analysis
Categorical data in contingency tables were analyzed with the Fisher's exact test and the Mantel-Haenszel chi-square test for trend. Continuous data were analyzed with the nonparametric Wilcoxon rank-sum test. Multivariable logistic regression was performed using standard techniques to model good outcome (mRS 0-2). Multivariable generalized ordinal logistic regression was performed using standard techniques to model the full range of the mRS, trichotomized as good outcome (mRS 0-2) vs. intermediate outcome (mRS 3-4) vs. poor outcome (mRS 5-6). In generalized ordinal logistic regression, predictors not meeting the proportional odds assumption have two different odds ratios presented for each of the two outcome transitions, while predictors meeting the proportional odds assumption have the same odds ratio for both. Receiver-operator characteristics (ROC) curves were constructed by plotting test sensitivity against (1specificity). We compared pairwise score discrimination for three-month outcomes by comparing the area under the curve (AUC) for ROC curves using the chi-square statistic. In cases in which a particular score could only be calculated for a subset of patients in the total dataset, only that subset of patients was used to perform the pairwise ROC curve comparison. All statistical analyses were performed using sas version 9·2 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Patient characteristics are summarized in Table 1 , which displays patient age, NIHSS, comorbidities (HTN, DM, and AF), and clinical prediction scores (THRIVE, HIAT, HIAT-2, and SPAN-100) according to each of three categories: all patients treated with the Solitaire device in SWIFT and STAR (n = 291), patients randomized to the Merci device in SWIFT (n = 58), and patients randomized to the Solitaire device in SWIFT (n = 55).
THRIVE score and clinical outcomes in Solitaire-treated patients in SWIFT and STAR
Increasing THRIVE score strongly predicts a decreasing chance of good outcome (mRS of 0-2 at three-months, Fig. 1a ; P < 0·001, Mantel-Haenszel chi-square test for trend) and increased chance of death by three-months ( Fig. 1b ; P < 0·001, Mantel-Haenszel chi-square test for trend) among all patients treated with Solitaire in SWIFT and STAR.
THRIVE score and clinical outcomes in the SWIFT RCT
Increasing THRIVE score strongly predicts a decreasing chance of good outcome (mRS of 0-2 at 3 months, Fig. 2a ; P < 0·001, Mantel-Haenszel chi-square test for trend) and increased chance of death by three-months ( Fig. 2b ; P < 0·001, Mantel-Haenszel chi-square test for trend) among all patients in the RCT component of SWIFT (treatment with either the Merci device or the Solitaire device).
Independence of THRIVE score and recanalization or treatment assignment
We have previously found that THRIVE score predicts outcomes independent of recanalization therapy with intravenous (IV) tPA (6, 7) or recanalization success with EST (2, 4, 5) . Similarly, EST treatment assignment in the TREVO-2 RCT did not alter the relationship between THRIVE and outcome (5) . In other words, the relative impact of THRIVE score on outcomes is not modified by successful recanalization during EST or the type of recanalization therapy used, and the relative impact of recanalization therapy on clinical outcomes is not modified by the patient's THRIVE score (2, 4, 5) .
Among patients treated with the Solitaire device in SWIFT and STAR, THRIVE score and recanalization are similarly independent and without interaction ( Table 2) . Controlling for successful recanalization does not alter the relationship between THRIVE score and good outcome ( 
ROC curve analysis comparing THRIVE with other outcome prediction scores
To better understand the relative utility of available ischemic stroke outcome prediction scores in the context of current generation EST devices, we used ROC curve analysis to compare the THRIVE score with other scores for which sufficient data were available for Solitaire-treated patients in SWIFT and STAR (HIAT, HIAT-2, and SPAN-100).
The ROC curves for the THRIVE score has a similar AUC in comparison with HIAT and HIAT-2 and is superior to the SPAN-100 ( Fig. 3a,b ). For prediction of poor outcome at three-months (mRS 3-6), the THRIVE ROC AUC is 0·68, compared with 0·68 for HIAT (P = 0·98), 0·66 for HIAT-2 (P = 0·54), and 0·55 for SPAN-100 (P < 0·001). For prediction of death by three-months, the THRIVE ROC AUC is 0·67 compared with 0·67 for HIAT (P = 0·94), 0·64 for HIAT-2 (P = 0·61), and 0·56 for SPAN-100 (P < 0·04). Similar results are found when the slightly different cut point for poor outcome used in the validation of HIAT (1) and HIAT-2 (3) is tested (mRS 4-6; Supporting Information Fig. S1 ).
Modeling of multiple outcome predictors in SWIFT + STAR
To examine the relative impact of several known predictors of outcome (including THRIVE score, time to procedure, device used, successful recanalization, symptomatic intracerebral haemorrhage (sICH), and use of general anesthesia) on outcomes, we performed generalized ordinal logistic regression modeling the Because of significant interaction between the device used (Solitaire vs. Merci) and rate of successful recanalization (TICI 2b/3), two models are presented, one with device used and the other with successful recanalization (Table 3) . Each predictor was found to independently predict outcome, with the notable exception of general anesthesia, which did not predict outcome in either model ( 
Discussion
We find that the THRIVE score strongly predicts clinical outcomes among acute stroke patients treated with a third generation EST device (the Solitaire device) in the SWIFT and STAR trials. The performance of the THRIVE score in the TREVO-2 trial is similar to or superior to other predictive scores (HIAT, HIAT-2, and SPAN-100).
The THRIVE score has been serially validated with similar robust performance across all acute ischemic stroke treatment contexts: IV tPA treatment (6,7), EST (2, 4, 5) , and no acute stroke treatment (6, 7) . In each of these contexts, including the present study, the THRIVE score has been found to predict outcomes independent of recanalization therapy, such that there is no interaction between the relationship between THRIVE and outcomes and the relationship between recanalization therapy and outcomes. It is likely that this consistent lack of interaction arises from the fact that the THRIVE score is composed of a set of non-modifiable predictors of outcome: the patient's age, the clinical severity of the stroke itself (NIHSS), and three medical comorbidities (HTN, DM, and AF).
The lack of interaction between THRIVE and recanalization/ device used has important implications for the use of THRIVE as a potential a priori patient screening tool for participation in clinical trials. Various inclusion/exclusion criteria have been used in EST trials to attempt to enroll only patients with an anticipated potential to benefit from recanalization therapy with an accept- able risk profile. One proposed patient selection approach is the use of advanced neuroimaging to determine the balance of ischemic penumbra to the territory at risk (12) . While advanced neuroimaging of magnetic resonance imaging diffusion and perfusion maps are predictive of final infarct volume (12) , initial attempts to use such techniques for RCT patient selection have not yet led to positive results (13) . Because a high THRIVE score (6 to 9) has been consistently found to predict poor outcomes in EST (2, 4, 5) and THRIVE consistently predicts outcomes in a fashion that does not interact with the relationship between recanalization and outcome, this means that at high THRIVE scores, the relative positive impact of successful recanalization only minimally impacts the absolute rate of good outcomes for such patients. It is therefore likely, based on these data, that screening using the easily determined THRIVE score in EST clinical trials should enrich such a trial's population for patients with a better chance of a good outcome after EST.
While the THRIVE score has been found to predict the risk of haemorrhage after tPA (6,7), we have not found evidence for a similar relationship between THRIVE and sICH in the context of EST (5) . However, because of the very low rate of sICH in both SWIFT and STAR (1·4%), we were not able to explore the relationship between THRIVE and sICH in the setting of Solitaire device use.
The THRIVE score continued to be a strong independent predictor of outcomes in well-specified models including other known predictors of outcome such as time to procedure, successful recanalization (TICI 2b/3), sICH, and use of general anesthesia (Table 3) . Of note, although other observational studies have suggested an association between general anesthesia and poor outcome (14), we do not find such an association in the SWIFT + STAR trials after controlling for THRIVE score, time, successful recanalization, and sICH.
In summary, the THRIVE score is an easy-to-use predictive score to assess post-stroke functional outcome and mortality in EST, and has now been validated in the context of both clinically available retrievable stent devices, the Solitaire device and the 
Generalized ordinal logistic regression models showing the relative impact of predictors on outcome across the range of the mRS, trichotomized as good outcome (0-2) vs. intermediate outcome (3) (4) vs. poor outcome (5-6). Odds ratios above 1 (with positive coefficients) represent a predictor that is associated with improved odds of a better outcome, and odds ratios below 1 (with negative coefficients) represent a predictor that is associated with reduced odds of a better outcome. In each model, odds ratios are shown for good outcome (mRS 0-2, on the left) and for good to intermediate outcome (mRS 0-4, on the right). For predictors meeting the proportional odds assumption for ordinal logistic regression, the same odds ratio value is presented for both outcome levels, indicated by an asterisk. For predictors failing to meet the proportional odds assumption, two different odds ratio values are presented for the two outcome levels. In Model 1, predictors are THRIVE score, time to treatment (onset to groin puncture in hours), treatment with the Solitaire device (vs. Merci device), occurrence of symptomatic intracerebral haemorrhage (sICH), and use of general anesthesia (vs. monitored anesthesia care without endotracheal intubation). In Model 2, predictors are THRIVE score, time to treatment (onset to groin puncture in hours), successful recanalization (TICI 2b/3), occurrence of sICH, and use of general anesthesia (vs. monitored anesthesia care without endotracheal intubation). Two separate models are shown because of significant interaction between use of the Solitaire device and the rate of successful recanalization. Patients treated with the Solitaire device were significantly more likely to have successful recanalization [(221/271 (81·5%)] than patients treated with the Merci device [22/53 (41·5%)] (P < 0·001). CI, confidence interval; mRS, modified Rankin Scale; OR, odds ratio; SE, standard error; THRIVE, Totaled Health Risks in Vascular Events; TICI, Thrombolysis in Cerebral Ischemia.
